About us

Mission statement

Mirabilis Therapeutics develops the next generation microRNA medicines in the areas of cardiovascular and metabolic disorders. Our mission is to become Europe’s number one microRNA developing and commercializing company, developing high medical need drugs for and in close collaboration with doctors and patients.


Mirabilis Therapeutics is a young Biotech company founded in 2015 as a spin off from the University of Maastricht and is based on the inventions made by the CARIM School for Cardiovascular Diseases of Maastricht University under the auspices of the laboratories of Prof. L. de Windt and Dr. P. da Costa Martins.